Skip to main content

10-12-2019 | Haematology | Video

ASH 2019 | Four cycles of R-CHOP confirmed as good approach for limited stage DLBCL

Daniel Persky gives the results of the large National Clinical Trials Network S1001 study, confirming the benefits of four cycles of R-CHOP for PET-negative patients with limited stage diffuse large B-cell lymphoma (2:57).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits